iRGD-modified manganese-porphyrin nanoparticles

Cross blood-brain barrier

A sonodynamic nanoplatform with active targeting and MRI tracking capability that penetrates the blood-brain barrier and enables real-time intracranial localization.

Yan, Chunhong · Chen, Wei · Tianan, Jiang · Xu, Danxia · Zhao, Qiyu · Lu, Qifeng · Xiaoying, Qiu · Wang, Baohua

Cancer Nanotechnology 2026

Advantages

Crosses the BBB

iRGD modification enables the nanoparticles to traverse the blood-brain barrier via active targeting, overcoming the obstacle of intracranial delivery for conventional sonosensitizers.

MRI-trackable

The manganese-chelated porphyrin endows the nanoparticles with T1-weighted MRI contrast capability, allowing real-time visualization of intracranial distribution and tumor accumulation.

Superior efficacy and survival

Upon ultrasound irradiation, iRGD-LP-DM elicited significantly stronger antitumor efficacy and prolonged survival in orthotopic glioma-bearing mice compared with all control groups.

Applications

• Brain drug delivery：Delivers sonosensitizers across the blood-brain barrier via iRGD, addressing intracranial drug delivery challenges.
• Tumor targeted therapy：Achieves tumor-selective accumulation and killing through iRGD-mediated active targeting of glioma cells.
• Sonodynamic therapy：Generates reactive oxygen species upon ultrasound activation to induce apoptosis in glioma cells.
• Multimodal theranostics：Integrates targeting, MRI imaging, and sonodynamic therapy into a single nanoplatform for theranostics.